Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease.

CGRP pathway inhibitors are effective treatments for preventing migraines. This study focused on their long-term safety in patients with previous cerebrovascular or cardiovascular diseases. Researchers analyzed data from a real-world registry at a Headache Centre. They included patients with a history of ischaemic stroke, transient cerebral ischaemic attack, or ischaemic heart disease. Out of 420 migraine patients, only 17 (4%) had these conditions. The average age of these patients was 54.5 years, and 76% were female. Most of these patients had chronic migraine, making up 82% of the group. The study followed these patients for a total of 31 patient-years. This research helps fill the gap in knowledge regarding the safety of CGRP inhibitors. It’s important because many patients with migraines also have other serious health issues. Clinical relevance: This study suggests CGRP pathway inhibitors are safe for migraine patients with prior vascular diseases.